New drug combo aims to tame rare kidney disease

NCT ID NCT06676579

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding avacopan (a pill that blocks inflammation) to low-dose steroids can help people with crescentic IgA nephropathy, a severe kidney condition. Sixteen adults with high-risk features will be randomly assigned to receive either avacopan plus low-dose steroids or standard high-dose steroids. The main goal is to see if protein in the urine drops significantly after 12 months, which would suggest less kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Avacopan (a drug that blocks a protein called C5a receptor, taken as a pill)
What this could lead to: If it works, this could offer a new treatment option for people with a severe form of IgA nephropathy, potentially reducing kidney damage and delaying or avoiding dialysis or transplant.
What could go wrong: This is a very small, early-phase trial with only 16 people, so results may not apply to everyone. The drug may not work better than standard steroids, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGA NEPHROPATHY (IGAN)

Contacts and locations

Locations

Mayo Clinic in Florida
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.